People with Laron syndrome have a low risk of heart disease and a number of other age-related disorders, hinting at ...

The availability of Vosoritide, a medication used for treatment of achondroplasia among children patients, will be widened ...

Paralympic champion Ellie Simmonds said she has found new motivation to “make life even easier for people like me” outside of ...

The cuts of four pipeline prospects come as BioMarin resets its priorities following the slow launch of its hemophilia gene therapy Roctavian.

A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia - the most common type of dwarfism - in a global trial led by Melbourne's ...

After BioMarin’s new leadership conducted a “strategic R&D asset review,” three of its “most productive” assets are being ...

Keep abreast with the latest news related to Achondroplasia there are 105 news items on Achondroplasia that covers updates, breakthroughs and in-depth reports. We provide you with a free ...

Q1 2024 Earnings Call Transcript April 24, 2024 BioMarin Pharmaceutical Inc. beats earnings expectations. Reported EPS is ...

In a report released yesterday, Geoff Meacham from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN – ...

On April 26, 2024, Biomarin Pharmaceutical Inc (NASDAQ:BMRN) filed its 10-Q report, revealing key financial and operational ...

Dublin, April 08, 2024 (GLOBE NEWSWIRE) -- The "Achondroplasia - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Market ...

BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in ...